Flibanserin is a prescription drug indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Pink Pill 100 is a medication used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It is specifically indicated for women who have not experienced low sexual desire in the past and whose low sexual desire is not caused by medical or psychiatric conditions, relationship issues, or the use of certain medications.
It's important to note that flibanserin is not intended for use by men or women who have already gone through menopause. The medication is available only through a special program, and patients must be registered in the program and have a clear understanding of the potential risks and benefits associated with its use.
If you are experiencing low sexual desire and are interested in exploring treatment options, it is recommended to consult with a healthcare professional who can assess your specific situation and provide appropriate guidance and recommendations. They will be able to determine if flibanserin or any other treatments are suitable for you.
Pink Pill 100 works by targeting and balancing certain neurotransmitters in the brain, specifically dopamine and norepinephrine, which play a role in sexual desire.
Common side effects of flibanserin include:
A prescription medication called flibanserin is used to treat premenopausal women who have acquired, generalized hypoactive sexual desire disorder (HSDD), which is characterized by low sexual desire that significantly affects their quality of life or interpersonal relationships.
Dopamine D(4k), serotonin 5-HT(1A), and serotonin 5-HT(2A) receptors are where flibanserin has a preferential affinity. Flibanserin acts as a 5-HT(1A) agonist, a very weak partial agonist on dopamine D(4) receptors, and a 5-HT(2A) antagonist in vitro and during micro iontophoresis. Flibanserin binds to 5-HT(1A) and 5-HT(2A) receptors equally in vivo. Flibanserin, however, may occupy 5-HT(2A) receptors in a higher proportion than 5-HT(1A) receptors when brain 5-HT levels are higher (i.e., under stress). Flibanserin differs from the claimed 5-HT(1A) receptor agonists buspirone and 8-OH-DPAT in how it affects adenylyl cyclase. The CA1 region of the brain is the most sensitive to flibanserin's effects, which include a decrease in neuronal firing rate in cells of the dorsal raphe, hippocampus, and cortex. The stimulation of postsynaptic 5-HT(1A) receptors appears to be the mechanism by which flibanserin reduces the firing rate in the cortex, whereas the stimulation of dopamine D(4) receptors appears to be the mechanism by which flibanserin reduces the number of active cells. Flibanserin increases tonic activation of postsynaptic 5-HT(1A) receptors in the CA3 area while rapidly desensitizing somatic 5-HT autoreceptors in the dorsal raphe. In the cortex, flibanserin preferentially decreases 5-HT production and extracellular levels while increasing NE and DA extracellular levels. In the majority of animal models that are susceptible to antidepressants, flibanserin exhibits antidepressant-like effects. However, this activity appears to be of a higher caliber than that produced by conventional antidepressants. In those animal models, flibanserin appears to function by either directly or indirectly stimulating the 5-HT(1A), DA, and opioid receptors. In animal models of anxiety, flibanserin does not consistently affect the animals, but it does appear to have antipsychotic potential. At pharmacologically significant concentrations, flibanserin may cause mild drowsiness but does not cause detectable toxic consequences.
Dosage & Administration:
Untaken Dosage:
There are no studies on pregnant women to inform whether there is a drug-associated risk in humans. Unknown if distributed in human breast milk and it is unknown whether flibanserin has effects on the breastfed infant or if it affects milk production.
Keep in a dry place away from light and heat. Keep out of the reach of children.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.